On August 11, Xunming Biotech announced the completion of Series B financing totaling 100 million US dollars. According to Xunming Biotechnology, this round of financing was completed in stages. Among them, the first round was exclusively invested by Granite Asia, the subsequent round was led by well-known industrial investors, followed by Honghui Fund, and existing shareholders such as Qiming Venture Capital, Jingwei Venture Capital, and Newley Capital continued to invest. So far, Xunming Biotech has raised nearly US$200 million. Xunming Biotech revealed that this round of financing will focus on the development and large-scale training of next-generation biobased models.
Zhitongcaijing · 2d ago
Share
Listen to the news
On August 11, Xunming Biotech announced the completion of Series B financing totaling 100 million US dollars. According to Xunming Biotechnology, this round of financing was completed in stages. Among them, the first round was exclusively invested by Granite Asia, the subsequent round was led by well-known industrial investors, followed by Honghui Fund, and existing shareholders such as Qiming Venture Capital, Jingwei Venture Capital, and Newley Capital continued to invest. So far, Xunming Biotech has raised nearly US$200 million. Xunming Biotech revealed that this round of financing will focus on the development and large-scale training of next-generation biobased models.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending